 | 
|
| |
|
Titel: Restless legs - vanligt sjukdomstillstånd som ofta missas. Möjligheter till framgångsrik behandling finns idag [summary] 2006 nr 4 sid 207-11
|
Summary:
Restless legs syndrome (RLS) is characterized by intense restlessness and unpleasant creeping sensations deep inside the lower legs. The symptoms appear when the limbs are at rest and are worst in the evening and at night. They force the patients to keep moving their legs, and sometimes to get out of bed and wander about. Periodic limb movements of the extremities (PLM) are common during sleep thus causing severe reduction in sleep efficiency. In many cases RLS may be an inherited disorder and there is a common association with iron deficiency anemia and chronic renal failure. The pathophysiology of RLS is multifactorial and incompletely understood. Results of dopaminergic treatment and recent data by advanced neuroimaging suggest that symptoms of RLS may be generated in the central nervous system, notably in substantia nigra, putamen and by rhythmically active nuclei in the thalamus, brainstem and cerebellum. RLS is a very common disorder but has not seldom been under-diagnosed and poorly treated for many years in general practice. At present there is a wide range of treatment options including levodopa, dopamine agonists, opioids, antiepileptic drugs and benzodiazepines.
Karl Ekbom, Lena Leissner, Jan-Edvin Olsson, Håkan Widner
Correspondence: Karl Ekbom, Neurologiska kliniken, Karolinska Universitetssjukhuset Huddinge, SE-141 86 Stockholm, Sweden
karl.ekbom@karolinska.se
Referenser:
1. Ekbom KA. Asthenia crurum paraesthetica (Irritable legs). Acta Med. Scand. 1944; 118:197-209.
2. Ekbom KA. Restless legs. Acta Med. Scand. 1945; Suppl.158: 1-123.
3. Ekbom KA. Restless legs syndrome. Neurology 1960; 10: 868-873.
4. Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med 2000; 1:11-9.
5. Winkelmann J, Muller-Myhsak M, Wittchen HU, Huck B, Prager M, Pfister H et al. Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families. Ann Neurol 2002; 52:297-302
6. Ondo WG, Dat Vuong K, Wang Q. Restless legs syndrome in monozygotic twins: Clinical Correlates. Neurology 2000; 55:1404-6.
7. Bonati MT, Ferini-Strambi L, Aridon P, Oldani A, Zucconi M, Casari G. Autosomal dominant restless legs syndrome maps on chromosome 14 q. Brain 2003; 126:1485-1492
8. Thambisetty M, Iranzo A, Hicks A, Kristjansson K, Hakonarson H, Eriksdotter I et al. Clinical features of restless legs syndrome in Iceland. Sleep 2004; 27 (Abstract Suppl.); 307-8.
9. Nordlander NB. Therapy in restless legs. Acta Med Scand 1953;145:453-7.
10. Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep 1994; 17: 739-43.
11. Hening W, Walters A, Allen R, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004;5:237-46.
12. Walters AS and The International Restless Legs Syndrome Study Group. Toward a better definition of the restless legs syndrome. Mov Disord 1995; 10: 634-42.
13. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. Sleep Med 2003; 4: 101-19.
14. Walters AS and The International Restless Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003 ; 4: 121-132.
15. Benca R, Quintans J. Sleep and host defenses: a review. Sleep 1997;20:1027-37.
16. Irwin M, Mc Clintick J, Costlow C, Fortner M, White J, Gillin J. Partial night sleep deprivation reduces natural killer and cellular immune responses in humans. FASEB J 1996;10:643-53.
17. Irwin M, Thompson J, Miller C, Gillin J, Ziegler M. Effects of sleep and sleep deprivation on catecholamine and interleukin-2 levels in humans: clinical implications. J Clin Endocrinol Metab 1999;84:1979-85.
18. Savard J, Laroche L, Simard S, Ivers H, Morin C. Chronic insomnia and immune functioning. Psychosom Med 2003;65:211-21.
19. Nilsson P, Nilsson J-Å, Hedblad B, Berglund G. Sleep disturbancies interacts with elevated pulse rate for the prediction of mortality - Consequences of mental strain? J Internal Med 2001;250:520-5.
20. Bonnet M, Arand D. Heart rate variability in insomniacs and matched normal sleepers. Psychosom Med 1998;60:610-5.
21. Schwartz SW, Cornoni-Huntley J, Cole SR, Hays JC, Blazer DG, Schocken DD. Are sleep complaints an independent risk factor for myocardial infarction? Ann Epidemiol 1998;8:384-92.
22. Ayas NT, White DP, Manson JA, Stampfer MJ, Speizer FE, Malhotra A et al. A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med 2003;163:205-9.
23. Meier-Ewert H, Ridker P, Rifai N, Regan M, Price N, Dinges D et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. JACC 2004;43:678-83.
24. Rööst M, Nilsson P. Sleep disorders - metabolic implications and long-term risks. Läkartidningen 2002;99:154-7.
25. Spiegel K, Ledproult R, van Cauter E. Impact of sleep debt on metabolism and endocrine function. Lancet 1999;354:1435-9.
26. Palatini P, Casiglia E, Pauletto P, Staessen J, Kaciroti N, Julius S. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysisin three populations. Hypertension 1997;30:1267-73.
27. Björntorp P, Holm G, Rosmond R. Hypothalamic arousal, insulin resistance and type 2 diabetes mellitus. Diab Med 1999;16:373-83.
28. Ulfberg J, Nyström B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18-64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord 2001;16:1159-63.
29. Rothdach A, Trenkwalder C, Haberstock J, Keil U, Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and morbidity in Augsburg elderly. Neurology 2000;54:1064-8.
30. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiological features. J Clin Neurophysiol 2001;18:128-47.
31. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. et al. Clinical, polysomnographic and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997;12:61-5.
32. Coleman RM. Periodic movements in sleep (nocturnal myoclonus) and restless legs syndrome. In: Guilleminault C, editor. Sleeping and waking disorders: indications and techniques. Menlo Park CA: Addison-Wesley; 1982. p. 265-95.
33. The Atlas Task Force of the American Sleep Disorders Association, Recording and scoring leg movements. Sleep 1993;16:748-59.
34. Bara-Jimenez W, Aksu M, Graham B, Sato S, Hallett M. Periodic limb movements in sleep:state-dependent excitability of the spinal flexor reflex. Neurology 2000;54:1609-16.
35. Yokota T, Hirose K, Tanabe H, Tsukagoshi H. Sleep-related periodic leg movements due to spinal cord lesion. J Neurol Sci 1991;104:13-8.
36. Lee M, Choi Y, Lee S.H, Lee S.B. Sleep-related periodic leg movements associated with spinal cord lesions. Mov Disord 1996;11:719-22.
37. Bucher S, Seelos K, Oertel W, Reiser M, Trenkwalder C. Cerebral generators involved in the pathogenesis of the restless legs syndrome. Ann Neurol 1997;1:639-45.
38. Iriarte J, Urrestarazu E, Alegre M, Valencia M, Artieda J. Oscillatory cortical changes during periodic limb movements. Sleep 2004;27:1493-8.
39. Bixler E, Kales A, Vela-Bueno A, Jacoby J, Scarone S, Soldatos C. Nocturnal myoclonus and nocturnal myoclonic activity in a normal population. Res Commun Chem Pathol Pharmacol 1982;36:129-40.
40. Youngstedt S, Kripke D, Klauber M et al.Periodic leg movements during sleep and sleep disturbances in elders. J Gerontol A Biol Sci Med Sci 1998;53:391-4.
41. Dickel M, Mosko S. Morbidity cut-offs for sleep apnea and periodic leg movements in predicting subjective complaints in seniors. Sleep 1990;13:155-66.
42. Montplaisir J, Michaud M, Denesle R, Gosselin A. Periodic leg movements are not more prevalent in insomnia or hypersomnia but are specifically associated with sleep disorders involving a dopaminergic impairment. Sleep Med 2000;1:163-7.
43. Ekbom KA. Restless legs som tidigsymtom vid cancer. Läkartidningen 1955;52:1875-82.
44. Aspenström G. Pica och restless legs vid järnbrist. Läkartidningen 1964;61:1174-7.
45. Ekbom K. Restless legs syndrome after partial gastrectomy. Acta Neurol Scand 1966;42:79-89.
46. Ulfberg J, Nyström B. Restless legs syndrome in blood donors. Sleep Med 2004;5:115-8.
47. Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. Sleep 1998; 21: 371-7.
48. Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome ( RLS ). Sleep Med 2004;5:385-391.
49. Brittenham GM. Disorders of iron metabolism: iron deficiency and overload. In: Hoffman R. Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, editors. Hematology: basic principles and practice. New York: Churchill Livingstone; 2000. p. 397-428.
50. Allen RP, Barker PB, Wehrl F, Song HK, Earley CJ. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001;56:263-5.
51. Connor JR, Boyer PJ, Menzies SL, Dellinger B, Allen RP, Ondo WG et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003;61:304-9.
52. Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000;54:1698-1700.
53. Mizuno S, Mihara T, Miyoaka T, Inagaki T, Horiguchi J. CSF iron, ferritin and transferring levels in restless legs syndrome. J Sleep Res. 2005; 14: 43-7.
54. Scales WE, Vander AJ, Brown MB, Kugler MJ, Human circadian rhythms in temperature, trace metals, and blood variables. J Appl Physiol 1988;65:1840-6.
55. Grote L, Hedner J, Leissner L, Ulfberg J. Iron sucrose (Venofer ) reduces symptoms of restless legs; a randomised, double-blind, placebo-controlled comparison. Svenska Läkaresällskapets Riksstämma, Göteborg, 2004, Neurospecialiteter 9 P.
56. Eisensehr I, Wetter TC, Linke R, Noachtar S, v Lindeleiner H, Gildehaus FJ et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001; 57: 1307-9.
57. Ruottinen HM, Partinen M, Hublin C, Bergman J, Haaparanta M, Solin O, Rinne JO. A FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000;54:502-4.
58. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999; 52: 932-7.
59. von Spiczak S, Whone AL, Hammers A, Asselin MC, Turkheimer F, Tings T, Happe S, Paulus W, Trenkwalder C, Brooks DJ. The role of opioids in restless legs syndrome: [11C]diprenorphine PET study. Brain 2005 Feb 23 (e-publ).
60. Earley C. Restless legs syndrome. N Engl J Med 2003; 348: 2103-9.
61. Garcia-Borreguero D, Odin P, Schwarz C. Restless legs syndrome: an overview of the current understanding and management. Acta Neurol Scand 2004; 109:303-17.
62. Chaudhuri KR, Olanow CW, Odin P (editors). Restless Legs Syndrome. London-New York: Taylor & Francis, A Parthenon Book. 2004. 147 pp.
63. Akpinar, S.: Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 1982; 39: 739.
64. Akpinar, S.: Restless legs syndrome treatment with dopaminergic drugs. Clin Neuropharmacol 1987; 10: 69-79.
65. von Scheele, C.: Levodopa in restless legs. Lancet 1986; 2:426-7.
66. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-13.
67. Hening WA, Allen RP, Earley CJ, Picchietti DL, Silber MH. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004;27:560-83
68. Comella CL. Restless legs syndrome. Treatment with dopaminergic agents.- Neurology 2002; 58 (Suppl. 1): S 87- S 92.
69. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole. A double-blind randomized trial. Neurology 1999;52: 938-43.
70. Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 2000; 7 (suppl 1): 27-31.
71. Ondo W. Ropinirole for restless legs syndrome. Mov Disord 1999; 14: 138-40.
72. Trenkwalder C, Garcia-Borreguero D, Montagna P, Lainey E, de Weerd AW, Tidswell P. et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75:92-7.
73. Stiasny-Kolster K, Benes H, Peglau I, Hornyak M, Holinka B, Wessel K, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology. 2004;63:2272-9.
74. Dhawan V, Medcalf P, Stegie F, Jackson G, Basu S, Luce P et al. Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson´s disease patients treated with cabergoline. J Neural Transm 2005; e-publ March 23.
75. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S et al. Severe multivalvular heart disease: A New complication of the ergot derivative dopaminre agonists. Mov Disord 2004; 19: 656-62.
76. Walters AS, Wagner ML, Hening WA, Grasing K, Mills R, Chokroverty et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993;16:327-32.
77. Trenkwalder C, Paulus W, Walters AS: The restless legs syndrome. Lancet Neurology 2005; 4: August: 465-75.
 207 |
 208 |
 209 |
 210 |
 211 |